<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>牛津和阿斯利康Covid-19疫苗：“效价计算错误” Oxford and AstraZeneca Covid-19 vaccine: "potency miscalculation"</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">Oxford and AstraZeneca Covid-19 vaccine: "potency miscalculation"<br/>牛津和阿斯利康Covid-19疫苗：“效价计算错误” </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2020-12-27 12:11:24</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2020/12/a50408a8b5cb37f9e86e2d03f2e12f6a.jpeg"><img src="http://img2.diglog.com/img/2020/12/a50408a8b5cb37f9e86e2d03f2e12f6a.jpeg" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>LONDON (Reuters) - On June 5, researchers at the University of Oxford quietly made a change to a late-stage clinical trial of their COVID-19 vaccine. In an amendment noted in a document marked CONFIDENTIAL, they said they were adding a new group of participants.</p><p>伦敦（路透社）-6月5日，牛津大学的研究人员悄悄地对其COVID-19疫苗的后期临床试验进行了更改。他们在一份标记为机密的文件中指出的一项修正案中说，他们正在增加一组新的参与者。</p><p>  The adjustment might seem minor in a large-scale study. But it masked a mistake that would have potentially far-reaching consequences: Many of the United Kingdom trial subjects had inadvertently been given only about a half dose of the vaccine.</p><p>  在大规模研究中，该调整可能看起来很小。但这掩盖了可能造成深远影响的错误：许多英国试验对象无意间只得到了一半剂量的疫苗。</p><p>  Much was riding on the Oxford vaccine, a British-led endeavour also involving UK drugs firm AstraZeneca. Prime Minister Boris Johnson’s government was desperate for a success story after its early mishandling of the pandemic contributed to one of the world’s highest death tolls from COVID-19 - around 65,000 by mid-December. The government has secured 100 million doses.</p><p>  英国人领导的努力也涉及英国药物公司阿斯利康的牛津疫苗。总理鲍里斯·约翰逊（Boris Johnson）的政府迫切希望获得成功，因为它对流感大流行的早期处理不力导致全球COVID-19死亡人数最高之一，到12月中旬，死亡人数约为65,000。政府已获得1亿剂。</p><p> On Nov. 23, Oxford and AstraZeneca delivered positive news. They announced that the regimen of a half dose followed by a full dose booster appeared to be 90% effective in preventing COVID-19. Two full doses scored 62%. Oxford researchers have said they aren’t certain why the half-dose regimen was much more effective.</p><p> 11月23日，牛津和阿斯利康发出了喜讯。他们宣布，半剂量方案后加全剂量加强剂在预防COVID-19方面似乎有90％有效。两次全剂量得分为62％。牛津大学的研究人员表示，他们尚不确定为什么半剂量疗法更有效。</p><p> Johnson called the vaccine team and tweeted his thanks “for their brilliant work.” He went on, “These results are incredibly encouraging and a major step forward in our fight against COVID-19.”</p><p> 约翰逊致电疫苗小组，并在推文中感谢“他们的出色工作。”他继续说道：“这些结果令人鼓舞，这是我们与COVID-19作战的重要一步。”</p><p> Oxford and AstraZeneca are now hoping for quick authorization by Britain’s regulator. But questions about the trial and the results won’t go away.</p><p> 牛津和阿斯利康现在希望得到英国监管机构的快速批准。但是有关审判和结果的问题不会消失。</p><p> Some experts say the dosing discrepancy raises doubts about the robustness of the study’s findings. And they worry about another acknowledged peculiarity of the study: The half-dose regimen wasn’t tested on anyone over 55 - the group considered at high risk from COVID-19. In contrast, a vaccine produced by Pfizer/BioNTech was tested on thousands of people over 65, with an efficacy of 94%.</p><p> 一些专家说，剂量差异使人们对该研究结果的可靠性产生怀疑。他们担心这项研究的另一个公认的特殊性：半剂量方案并未在55岁以上的任何人身上进行测试-该组被认为是COVID-19的高危人群。相比之下，辉瑞/ BioNTech生产的疫苗已在数千名65岁以上的人群中进行了测试，功效为94％。 </p><p> John Moore, a professor of microbiology and immunology at Weill Cornell Medical College in New York, said there needed to be a better understanding of how the Oxford trial unfolded. “When you get corporate and academic scientists saying different things, it doesn’t give you the impression of confidence in what they’re doing,” he told Reuters. “Was the dosing thing a mistake or not?”</p><p>纽约威尔康奈尔医学院微生物学和免疫学教授约翰·摩尔说，需要对牛津试验的进展情况有更好的了解。他告诉路透社：“当公司和学术界的科学家发表不同的看法时，这并不会给您带来对他们所做的事情充满信心的印象。” “加药是否错误？”</p><p> Now a Reuters review of hundreds of pages of clinical trial records, as well as interviews with scientists and industry figures, provides the most detailed account to date of what went wrong with the dosing in the Oxford/AstraZeneca vaccine study. The review found that Oxford researchers were responsible for what their own clinical trial documents called “a potency miscalculation.”</p><p> 现在，路透社对数百页临床试验​​记录进行的回顾，以及对科学家和行业人物的采访，提供了迄今为止最详细的关于牛津/阿斯利康疫苗研究​​中给药方式出问题的详细信息。该评论发现，牛津大学的研究人员应对他们自己的临床试验文件所称的“效能估计错误”负责。</p><p> For Oxford and AstraZeneca, the stakes could not be higher. They hope to produce up to three billion doses of the low-cost vaccine by the end of next year, enough to inoculate much of the world, including many of its poorest inhabitants. For months, scientists at Oxford have been busily promoting the experimental vaccine’s prospects in bullish terms - beginning even before the first human test subjects were injected with the experimental vaccine.</p><p> 对于牛津和阿斯利康而言，赌注再高不过了。他们希望在明年年底之前生产出多达30亿剂的低成本疫苗，足以接种世界上许多地方，包括许多最贫困的居民。几个月以来，牛津大学的科学家一直在忙于以看涨的眼光推广实验疫苗的前景，甚至是在第一个人类测试对象注射实验疫苗之前就开始了。</p><p>  In an interview that appeared on April 11 in Britain’s The Times newspaper, Sarah Gilbert, one of the vaccine’s chief researchers at Oxford, said she was 80% certain her team would be able to produce a successful vaccine, possibly as early as September. That was 12 days before a clinical trial to test its safety began.</p><p>  在4月11日发表在英国《泰晤士报》上的一次采访中，牛津大学疫苗的首席研究员之一莎拉·吉尔伯特说，她有80％的信心可以确定她的团队能够生产成功的疫苗，可能最早在9月。在进行临床试验以测试其安全性之前12天。</p><p> Oxford didn’t answer detailed questions for this story, but provided a statement saying the trials have been “conducted under the strict national, ethical and regulatory requirements.” It added that “all trial protocols and trial amendments have been subject to review and approval by the relevant authorities. All safety data have been reviewed regularly” by regulators.</p><p> 牛津大学没有回答有关这个故事的详细问题，但发表声明说，这些试验“是在严格的国家，道德和法规要求下进行的”。它补充说：“所有试验方案和试验修正案均须经有关当局审查和批准。监管机构定期对所有安全数据进行审查。</p><p> A spokesman for AstraZeneca referred questions about the UK clinical trial to Oxford, which sponsored it. A spokeswoman for Britain’s regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), declined to answer questions about the Oxford/AstraZeneca dosing issue. “Our rolling review is ongoing,” she said, “so this information is currently commercially confidential.”</p><p> 阿斯利康（AstraZeneca）的发言人将有关英国临床试验的问题转交给了牛津大学（Oxford）赞助。英国监管机构药品和保健产品监管局（MHRA）的发言人拒绝回答有关牛津/阿斯利康剂量问题的问题。她说：“我们正在进行滚动审查，因此，此信息目前在商业上是机密的。”</p><p>   Vaccines are the world’s best hope of ending a pandemic that has claimed more than 1.7 million lives globally. More than 60 COVID-19 vaccine candidates are currently undergoing human trials, according to the World Health Organization.</p><p>   疫苗是世界上最大的希望，以结束这场在全球造成170万人死亡的大流行。根据世界卫生组织的数据，目前有60多种候选COVID-19疫苗正在接受人体试验。 </p><p> Vaccines made by Pfizer/BioNTech and Moderna have already been authorized for use in some countries, including the United States. They use a relatively new technology called messenger RNA (mRNA) that instructs human cells to produce antigens, a type of protein, that stimulate the immune system. Late-stage clinical trials showed both vaccines appeared to be at least 94% effective. Until the UK approved the Pfizer/BioNTech vaccine on Dec. 2, no RNA vaccine had ever received authorization for general use.</p><p>辉瑞/ BioNTech和Moderna生产的疫苗已被授权在某些国家使用，包括美国。他们使用一种称为信使RNA（mRNA）的相对较新的技术来指导人类细胞产生抗原（一种蛋白质），从而刺激免疫系统。后期临床试验表明，两种疫苗似乎至少有94％有效。在英国于12月2日批准辉瑞/ BioNTech疫苗之前，没有任何RNA疫苗获得过通用授权。</p><p> The Oxford/AstraZeneca COVID-19 vaccine employs a more established technique called viral vector. The vaccine uses a bioengineered version of a harmless common-cold virus found in chimpanzees to instruct human cells to make antigens.</p><p> Oxford / AstraZeneca COVID-19疫苗采用了一种更为成熟的技术，称为病毒载体。该疫苗使用在黑猩猩中发现的无害普通感冒病毒的生物工程版本来指导人类细胞产生抗原。</p><p> On Dec. 8, Oxford published an interim analysis of its trial results and more than 1,100 pages of supplementary documents in the scientific journal The Lancet. These show that measuring the concentration of viral materials can be tricky, and they shed light on the chain of events leading up to the dosing discrepancy.</p><p> 12月8日，牛津大学在科学杂志《柳叶刀》上发表了其试验结果的中期分析和1,100多页的补充文件。这些表明，测量病毒物质的浓度可能很棘手，并且可以揭示导致剂量差异的一系列事件。</p><p> Viral vectors are typically produced in bioreactors holding up to 2,000 liters, which are then filtered and purified into a concentrated batch of active substance of just a few liters.</p><p> 病毒载体通常在容量高达2,000升的生物反应器中生产，然后将其过滤并纯化成浓缩的几升活性物质。</p><p>  “This is not about measuring pencils, pens, bricks, or fixed objects of a given size,” said Lucio Rovati, chief executive of Rottapharm, an Italian biotech company that is trying to develop a different type of vaccine using a genetic fragment. “It’s about live biological products.”</p><p>  意大利生物技术公司Rottapharm的首席执行官Lucio Rovati说：“这并不是要测量给定大小的铅笔，钢笔，砖头或固定物体，”该公司正尝试使用基因片段开发另一种类型的疫苗。 “这是关于活生物产品的。”</p><p> According to the Oxford documents, in May researchers received a vaccine delivery from Italy’s IRBM/Advent — one of the contract manufacturers Oxford enlisted to complement its own vaccine production. The late-stage trial of the Oxford vaccine was about to begin.</p><p> 根据牛津的文件，5月，研究人员从意大利的IRBM / Advent那里收到了疫苗的交付。该公司是牛津争取其自身疫苗生产的合同制造商之一。牛津疫苗的后期试验即将开始。</p><p> The shipment, batch K.0011, had undergone the Italian company’s quality check using an established genetic test - quantitative PCR, or qPCR - to determine viral matter per milliliter.</p><p> 这批货物K.0011已通过意大利公司的质量检查，采用的是既定基因测试-定量PCR或qPCR-以确定每毫升的病毒物质。 </p><p> Oxford ran its own analysis for good measure. The university had been using a different method known as spectrophotometry, which measures viral material in liquids based on how much ultraviolet light the viral matter absorbs.</p><p>牛津大学进行了很好的分析。该大学一直在使用另一种称为分光光度法的方法，该方法根据病毒吸收的紫外线量来测量液体中的病毒物质。</p><p> Oxford’s measurement showed that the batch was more potent than the Italian manufacturer had found, the documents show. Oxford trusted its own result and wanted to remain consistent with a measuring tool it had used throughout an earlier trial phase. So it asked Britain’s drugs regulator for permission to reduce the volume of vaccine injected into trial participants from the K.0011 batch. Permission was granted.</p><p> 文件显示，牛津大学的测量表明，这批产品比意大利制造商发现的产品更有效。牛津大学相信自己的结果，并希望与在整个早期试验阶段使用的测量工具保持一致。因此，它要求英国药品监管机构批准减少K.0011批次向试验参与者注射的疫苗数量。许可被授予。</p><p> “The decisions about dosing were all done in discussion with the regulator. So when we started the trial, we had some discrepancies in the measurement of the concentration of virus in the vaccine,” Andrew Pollard, the Oxford trial’s chief investigator, told Reuters.</p><p> “有关剂量的决定都是在与监管机构讨论后做出的。因此，当我们开始试验时，在疫苗中病毒浓度的测量上存在一些差异。”牛津试验首席研究员安德鲁·波拉德（Andrew Pollard）告诉路透社。</p><p> A spokeswoman for the regulator declined to discuss when it first became aware of the dosing issue.</p><p> 监管机构的一位女发言人拒绝讨论何时首次意识到剂量问题。</p><p>  Trial participants who received shots from the Italian batch displayed milder than normal expected side effects, such as fever and fatigue. AstraZeneca executive vice president Mene Pangalos said the dose was measured incorrectly. “It ended up being half the dose,” he told Reuters. He called the mistake “serendipity,” given that data analysis later indicated the half dose, followed by a full-dose booster shot, was much more effective than two full doses.</p><p>  从意大利批次中注射疫苗的试验参与者显示出比正常预期的副作用轻，如发烧和疲劳。阿斯利康执行副总裁梅内·潘加洛斯（Mene Pangalos）说，剂量的计算不正确。他告诉路透社：“最终剂量只有一半。”他称此错误为“偶然性”，因为后来的数据分析表明，半剂量然后加一剂全剂量的助剂比两剂更有效。</p><p> He also recently told the BBC: “There is no doubt I think that we would have run the study a little bit differently if we had been doing it from scratch. But ultimately, it is what it is.”</p><p> 他最近还对英国广播公司说：“毫无疑问，我认为如果我们从头开始进行这项研究，我们会做得有些不同。但最终，它就是它。”</p><p>  IRBM/Advent told Reuters there was no manufacturing issue with the batch. The company said in a written statement that the measuring mishap was “the result of a change in the testing method” used to confirm the potency of the dose “once the material had been shipped.”</p><p>  IRBM / Advent告诉路透社，这批产品没有制造问题。该公司在一份书面声明中说，测量事故是“测试方法改变的结果”，用于“一旦材料被运输”就确认剂量的效力。 </p><p> The documents published in The Lancet confirm that the error lay with the Oxford researchers. A common emulsifier, polysorbate 80, used in vaccines to facilitate mixing, had interfered with the ultraviolet-light meter that measures the quantity of viral material, according to the documents. As a result, the vaccine’s viral concentration was overstated and Oxford ended up administering half doses of vaccine, believing they were full doses.</p><p>《柳叶刀》上发表的文件证实了牛津大学研究人员的错误。根据文件显示，用于疫苗中以促进混合的普通乳化剂聚山梨酯80干扰了测量病毒物质含量的紫外​​光度计。结果，该疫苗的病毒浓度被夸大了，牛津大学认为该疫苗是全剂量的，因此最终只投了一半剂量。</p><p> The documents don’t give a detailed timeline, nor do they show that Oxford informed AstraZeneca at the time. But they do show that Oxford contacted the British regulator again, this time seeking approval to change its measuring method to the one used by the Italians, and to figure out how to proceed with a late-stage trial that had begun with participants receiving the wrong dose. The documents don’t provide full details of the communication between Oxford and the regulator.</p><p> 这些文件没有提供详细的时间表，也没有显示牛津当时已通知阿斯利康。但它们确实表明，牛津大学再次与英国监管机构联系，这次寻求批准将其测量方法更改为意大利人使用的测量方法，并弄清楚如何进行一项后期试验，该试验从参与者收到错误信息开始剂量。这些文件并未提供牛津大学与监管机构之间沟通的完整细节。</p><p> In early June, the regulator gave the green light to continue injecting people with the half-dose, in an effort to keep the trial as large as possible and to try to speed up the results, according to the analysis published in The Lancet. The regulator also ruled that Oxford must add another test group to receive the full dose, in accordance with its original plan to test the safety and efficacy of full doses.</p><p> 根据《柳叶刀》上发表的分析，6月初，监管机构批准继续向半剂量的人注射药物，以保持尽可能大的试验规模，并试图加快试验结果。监管机构还裁定，牛津必须按照其最初计划测试全剂量的安全性和有效性，再增加一个测试组以接受全剂量。</p><p> “We went back and discussed it again with the regulators and agreed with them,” said Pollard, the Oxford study’s chief investigator.</p><p> 牛津研究的首席研究员波拉德说：“我们回过头来，再次与监管者讨论，并同意他们的意见。”</p><p> Ultimately, 1,367 trial participants - none of them over 55 - received the half-dose/full-dose regimen. Two full doses were given to 4,440 adult participants, from all age groups.</p><p> 最终，有1,367名试验参与者-他们中的55岁以上无一人-接受了半剂量/全剂量方案。对所有年龄段的4,440名成年参与者进行了两次全剂量治疗。</p><p> The MHRA, Britain’s regulator, is expected to decide soon whether to approve the vaccine. The agency is headed by June Raine, a doctor who trained in general medicine at Oxford. The university’s website shows she has made donations, given talks and performed volunteer work for the university’s Somerville College, which she attended.</p><p> 英国监管机构MHRA有望很快决定是否批准该疫苗。该机构由牛津大学普通医学培训医生朱恩·雷恩（June Raine）领导。该大学的网站显示她为该大学的萨默维尔学院（Somerville College）捐款，进行了演讲并进行了志愿者工作。</p><p> The MHRA said that before any decision on the Oxford/AstraZeneca vaccine is made, Raine “will ensure, for complete transparency” her interactions with Oxford as an alumnus are declared. It added that “none of these ties are of a nature that could give rise to a conflict requiring recusal.”</p><p> MHRA表示，在对牛津/阿斯利康疫苗做出任何决定之前，雷因“将确保为完全透明”宣布其与校友的互动。它补充说：“这些联系中的任何一种都不会引起需要撤回的冲突。” </p><p>  Deep within the more than 1,100 pages of supplemental appendices published in The Lancet appeared a description of the dosing discrepancy — “a potency miscalculation.” That admission is contained in a “Statistical Analysis Plan” by Oxford and AstraZeneca dated Nov. 17.</p><p>在《柳叶刀》上刊登的1,100多页补充附录的最深处，出现了剂量差异的描述-“效能错误计算”。牛津大学和阿斯利康大学在11月17日发布的“统计分析计划”中包含了这一承认。</p><p>  Six days later, Oxford and AstraZeneca announced the interim results of their clinical trials in the UK and in Brazil. “Oxford University breakthrough on global COVID-19 vaccine,” was the headline of an Oxford press release.</p><p>  六天后，牛津和阿斯利康宣布了在英国和巴西的临床试验的中期结果。牛津新闻稿的标题是“牛津大学在全球COVID-19疫苗方面的突破”。</p><p> AstraZeneca’s news release was more muted. “Two different dosing regimens demonstrated efficacy with one showing a better profile,” it stated.</p><p> 阿斯利康的新闻发布更加平静。它说：“两种不同的给药方案显示出疗效，其中一种显示出更好的效果。”</p><p> In interviews about the results with Reuters and the New York Times, AstraZeneca’s Pangalos spoke of “serendipity,” a “useful mistake” and a “dosing error.”</p><p> 在接受路透社和《纽约时报》采访时，阿斯利康的Pangalos谈到了“偶然性”，“有用的错误”和“剂量错误”。</p><p> But the firm’s chief executive officer, Pascal Soriot, told Bloomberg: “People call it a mistake — it was not a mistake.” A spokesman for AstraZeneca declined to comment on the statements.</p><p> 但该公司首席执行官帕斯卡尔·索里奥特（Pascal Soriot）告诉彭博社：“人们称其为错误-这不是错误。”阿斯利康的一位发言人拒绝对此发表评论。</p><p> Meanwhile, the two scientists leading Oxford’s development of the vaccine — Sarah Gilbert and Adrian Hill — suggested that the half-dose was not administered by mistake. They didn’t provide evidence. Gilbert, an Oxford vaccinology professor, said it was normal for researchers to look at different dose levels during vaccine trials. “It wasn’t a mix-up in dosing,” she told the Financial Times in an article published on Nov. 27.</p><p> 同时，领导牛津大学研制该疫苗的两位科学家萨拉·吉尔伯特和艾德里安·希尔提出，半剂量注射并非错误。他们没有提供证据。牛津大学疫苗学教授吉尔伯特说，研究人员在疫苗试验期间研究不同的剂量水平是正常的。她在11月27日发表的一篇文章中对英国《金融时报》说：“这并不是定量的混合。”</p><p> A few days later, Hill told Reuters it was a conscious decision by researchers to administer a lower dose. “There had been some confusion suggesting that we didn’t know we were giving a half dose when we gave it — that is really not true,” he said.</p><p> 几天后，希尔告诉路透社，这是研究人员有意识地决定降低剂量的决定。他说：“有些混乱表明我们不知道在给药时要给一半剂量—的确是不正确的。” </p><p> Gilbert and Hill together have about a 10% stake in a private biotech firm called Vaccitech that was spun out of Oxford University, according to a filing with Companies House, the UK’s companies registry, dated Oct. 29. According to a spokeswoman for Vaccitech, the company transferred its rights to the vaccine to Oxford University’s research commercialization arm in exchange for a share of the revenue. “If the vaccine is successful then all shareholders and investors in the company could potentially indirectly benefit,” she wrote in an email.</p><p>根据10月29日提交给英国公司注册处Companies House的文件，吉尔伯特和希尔总共持有从牛津大学分拆出来的一家名为Vaccitech的私人生物技术公司约10％的股份。根据Vaccitech的一位女发言人，该公司将其疫苗的权利转让给了牛津大学的研究商业化部门，以换取一部分收益。她在一封电子邮件中写道：“如果疫苗成功，那么公司的所有股东和投资者都可能间接受益。”</p><p>  The conflicting explanations of what went wrong have drawn criticism from some experts. “Personally, I can say that I think their vaccine is much better than their communication,” said Guido Rasi, who until last month was executive director of the European Medicines Agency, the European Union’s regulator. He said the agency eventually will evaluate the trial data.</p><p>  关于错误原因的相互矛盾的解释引起了一些专家的批评。 “我个人可以说，我认为他们的疫苗比他们的交流要好得多。”吉多·拉西（Guido Rasi）说，他直到上个月一直是欧盟监管机构欧洲药品管理局（European Medicines Agency）的执行董事。他说，该机构最终将评估试验数据。</p><p>   For months, the Oxford/AstraZeneca vaccine was described by officials and in the media as the front-runner in the global race to produce a COVID-19 vaccine.</p><p>   几个月来，牛津/阿斯利康疫苗被官员和媒体描述为全球生产COVID-19疫苗的领跑者。</p><p> Britain’s health minister, Matt Hancock, told a press conference in April that Britain was “at the forefront of the global effort” to find a vaccine.</p><p> 英国卫生部长马特·汉考克（Matt Hancock）在4月的一次新闻发布会上说，英国“在寻找疫苗的全球努力中处于最前沿”。</p><p> On June 26, the World Health Organization’s chief scientist, Soumya Swaminathan, said at a press conference that Oxford’s vaccine was probably the world’s leading candidate.</p><p> 6月26日，世界卫生组织的首席科学家Soumya Swaminathan在一次新闻发布会上说，牛津疫苗可能是世界领先的候选疫苗。</p><p> Five days later, the then head of Britain’s vaccine procurement program, Kate Bingham, told a parliamentary committee: “Oxford is ahead of the world in that it is the most advanced vaccine anywhere.”</p><p> 五天后，当时的英国疫苗采购计划负责人凯特·宾厄姆（Kate Bingham）对议会委员会说：“牛津大学在世界上领先，因为它是世界上最先进的疫苗。”</p><p> Some Oxford scientists did little to dampen the enthusiasm. Asked at the same science and technology parliamentary committee on July 1 whether the world would have to struggle through the coming winter without a vaccine, Gilbert said, “I hope we can improve on those timelines and come to your rescue.”</p><p> 牛津大学的一些科学家并没有采取任何行动抑制热情。 7月1日，在同一科学技术议会委员会上被问及世界是否需要在没有疫苗的情况下度过即将到来的冬天，吉尔伯特说：“我希望我们能在这些时间表上有所改善，并为您解救。” </p><p> At the end of July, she alluded to competing vaccine efforts. In an interview on the Royal Society of Biology’s website, she said of the Oxford/AstraZeneca vaccine: “If this doesn’t work, I don’t think anything will work.”</p><p>在7月底，她提到了疫苗竞争的努力。在英国皇家生物学会网站上的一次采访中，她谈到牛津/阿斯利康疫苗：“如果这种方法不起作用，我认为没有任何效果。”</p><p> Her main partner on the project, Hill, was equally bullish. On May 15, he told Reuters the Oxford/AstraZeneca candidate is “almost certainly the best single dose rapid-response vaccine.” He dismissed as “total unknowns” and a “wild card” the vaccines using mRNA technology, such as Pfizer/BioNTech and Moderna, which have since published results showing they were both at least 94% effective at preventing COVID-19. The Pfizer/BioNTech vaccine is already being distributed in the millions in the United States and the UK.</p><p> 她在该项目上的主要合伙人希尔同样乐观。 5月15日，他告诉路透社，牛津/阿斯利康的候选人“几乎可以肯定是最好的单剂量快速反应疫苗”。他将使用辉瑞/ BioNTech和Moderna等mRNA技术的疫苗称为“完全未知”和“通配符”，此后发表的结果表明，它们在预防COVID-19方面至少有94％的有效率。辉瑞/ BioNTech疫苗已经在美国和英国的数百万种疫苗中分发。</p><p> “Why would you take a vaccine technology that is new, unproven, maybe quick to manufacture, but expensive to manufacture - and has never been scaled up and has never been shown to protect against anything in humans, and prioritize that in a global emergency?” he asked. “It’s very odd.”</p><p> “为什么您会选择一种新的，未经验证的，可能快速制造的，但制造昂贵的疫苗技术，却从未扩大规模，也从未被证明能够预防人类的任何疾病，并在全球紧急情况下优先考虑这种疫苗技术？ ”他问。 “这很奇怪。”</p><p> Ian Jones, a professor of virology at Britain’s University of Reading, told Reuters that the plethora of upbeat statements hasn’t benefited the Oxford/AstraZeneca vaccine candidate.</p><p> 英国雷丁大学病毒学教授伊恩•琼斯（Ian Jones）告诉路透社，过多乐观的言论并没有使牛津/阿斯利康的候选疫苗受益。</p><p> “I don’t want to take away from the fact everybody has worked very hard and (the vaccine) is fundamentally safe and sound,” he said. “But reporting has always had a slightly nationalistic tone, which I don’t think has been helpful.”</p><p> 他说：“我不想摆脱每个人都非常努力并且疫苗基本上是安全无害的事实。” “但报告始终带有一点民族主义色彩，我认为这没有帮助。” </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://www.reuters.com/article/us-health-coronavirus-britain-vaccine-sp-idUKKBN28Y0XU">https://www.reuters.com/article/us-health-coronavirus-britain-vaccine-sp-idUKKBN28Y0XU</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/阿斯利康/">#阿斯利康</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/疫苗/">#疫苗</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/分享/">#分享</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy; 2020 diglog.com </div></div></body></html>